Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis

Journal of Hepatology

Volumn 38, Issue 5, 2003, Pages 660-667

  Medina, Jesús ^a   Caveda, Luis ^a   Sanz Cameno, Paloma ^a   Arroyo, Alicia G ^a   Martín Vílchez, Samuel ^a   Majano, Pedro L ^a   García Buey, Luisa ^a   Sánchez Madrid, Francisco ^a   Moreno Otero, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cell proliferation; Chronic hepatitis C associated angiogenesis; Endothelial cell; Hepatocyte growth factor; Intercellular adhesion molecule; Vascular endothelial growth factor

Indexed keywords

BETA CATENIN; BETA3 INTEGRIN; CADHERIN; CELL ADHESION MOLECULE; RECEPTOR ANTIBODY; SCATTER FACTOR; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR ANTIBODY;

ADULT; ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CHRONIC HEPATITIS; CONTACT INHIBITION; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LIVER; LIVER BIOPSY; MALE; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 0038555371     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00053-9     Document Type: Article

References (56)

1. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77.
2. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-1562.
3. García-Monzón C, Sánchez-Madrid F, García-Buey L, García-Arroyo A, García-Sánchez A, Moreno-Otero R. Vascular adhesion molecules expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology 1995;108:231-241.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
5. Nakamura T, Nishizawa T, Hagiya M, Scki T, Shimonishi A, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-443.
6. Gherardi E, Stroker M. Hepatocyte growth factor-scatter factor: mitogen, motogen and met. Cancer Cells 1991;3:227-232.
7. Okano JI, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999;19:151-159.
8. Okajima A, Miyazawa K, Naitoh Y, Inoue K, Kitamura N. Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Hepatology 1997;25:97-102.
9. Bussolino F, DiRenzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth. J Cell Biol 1992;119:629-641.
10. Grant SD, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-1941.
11. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation 1998;97:381-390.
12. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230.
13. Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J, et al. Functional properties of human vascular endothelial cadherin (7B4/Cadherin-5), an endothelial-specific cadherin. Arterioscler Thromb Vasc Biol 1995;15:1229-1239.
14. Caveda L, Martin-Padura I, Navarro P, Breviario F, Corada M, Gulino D, et al. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J Clin Invest 1996;98:886-893.
15. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997;349:490-495.
16. Adams DH, Hubscher SG, Fisher NC, Williams A, Robinson M. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996;24:533-538.
17. García-Monzón C, García-Buey L, Majano PL, Moreno-Otero R. Integrins: structure, biological functions and relevance in viral chronic hepatitis. Eur J Clin Invest 1995;25:71-78.
18. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-1230.
19. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of αvβ3 on vascular cells during wound repair. Am J Pathol 1996;148:1407-1421.
20. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-693.
21. Enenstein J, Waleh NS, Kramer RH. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992;203:499-503.
22. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-1814.
23. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelial cells. Proc Natl Acad Sci USA 1993;90:7533-7537.
24. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
25. Kang MA, Kim KY, Seol JY, Kim KC, Nam MJ. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J Gene Med 2000;2:289-296.
26. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273:15099-15103.
27. International Group. Acute and chronic hepatitis revisited. Lancet 1977;2:914-919.
28. Scheuer PJ, Ashrafzadeh P, Scherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-571.
29. Yáñez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, et al. Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol 1998;141:791-804.
30. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-693.
31. García-Monzón C, García-Buey L, García-Sánchez A, Pajares JM, Moreno-Otero R. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alpha-2b. Gastroenterology 1993;105:462-469.
32. Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration. Nat Cell Biol 2001;3:316-320.
33. Rosmorduc O, Wendum D, Corpechot C, Galy B, Sebbagh N, Raleigh J, et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 1999;155:1065-1073.
34. Shimoda K, Mori M, Shibuta K, Banner BF, Barnard GF. Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int J Oncol 1999;14:353-359.
35. Mazzanti R, Messerini L, Monsacchi L, Buzzelli G, Zignego AL, Foschi M, et al. CVH induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997;25:229-234.
36. Haratake J, Hisaoka M, Yamamoto O, Horie A. Morphological changes of hepatic microcirculation in experimental rat cirrhosis: a scanning electron microscopic study. Hepatology 1991;13:952-956.
37. Moriyama T, Kataoka H, Hamasuna R, Yokogami K, Uehara H, Kawano H, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 1998;249:73-77.
38. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999;79:427-438.
39. Castilla MA, Arroyo MV, Aceituno E, Aragoncillo P, Gonzalez-Pacheco FR, Texeiro E, et al. Disruption of cadherin-related junctions triggers autocrine expression of vascular endothelial growth factor in bovine aortic endothelial cells: effects on cell proliferation and death resistance. Circ Res 1999;85:1132-1138.
40. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111-1120.
41. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111:3621-3631.
42. Martin TA, Mansel R, Jiang WG. Hepatocyte growth factor modulates vascular endothelial-cadherin expression in human endothelial cells. Clin Cancer Res 2001;7:734-737.
43. Nieset JE, Redfield AR, Jin F, Knudsen KA, Johnson KR, Wheelock MJ. Characterization of the interactions of α-catenin with alpha-actinin and β-catenin/plakoglobin. J Cell Sci 1997;110:1013-1022.
44. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147-157.
45. Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J 2002;16:950-962.
46. Jiang WG, Martin TA, Matsumoto K, Nakamura T, Mansel RE. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol 1999;181:319-329.
47. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
48. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-571.
49. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest 1999;103:47-54.
50. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822.
51. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996;2:529-533.
52. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-693.
53. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001;98:119-124.
54. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-1263.
55. Schneller M, Vuori K, Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 1997;16:5600-5607.
56. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-892.